Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promixin inhalation for non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa infection
2016-004558-13Phase 3Completed
- Sponsor
- Zambon
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis and Pseudomonal infection comparing Promixin with Placebo (2 arms). Primary endpoint: Time to first pulmonary exacerbation. Started Mar 2017; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2016-004558-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004558-13.